Discovery of Novel Small Molecule Activators of β-Catenin Signaling
Author Information
Author(s): Folkert Verkaar, Mario van der Stelt, W. Matthijs Blankesteijn, Antoon A. van der Doelen, Guido J. R. Zaman
Primary Institution: Merck Research Laboratories, Oss, The Netherlands
Hypothesis
Can small molecule compounds activate β-catenin signaling in a cell-type specific manner?
Conclusion
The study identified small molecule compounds that activate Wnt/β-catenin signaling specifically in U2OS cells without affecting other cell types.
Supporting Evidence
- Three compounds were identified that activated β-catenin signaling in U2OS cells.
- Cpd1 and Cpd2 did not activate β-catenin signaling in other tested cell lines.
- The compounds did not inhibit GSK3 or any other kinases in a large panel of tests.
Takeaway
The researchers found new drugs that can help a specific signaling pathway in certain cells, which might help treat diseases like neurodegenerative disorders.
Methodology
The study screened a library of 2300 compounds using a β-galactosidase fragment complementation assay in U2OS cells.
Limitations
The exact molecular target of the compounds remains unidentified, and the activation was only observed in specific cell lines.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website